Cardiovascular Surgical Devices Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts

Cardiovascular Surgical Devices Market Size and Forecast 2025-2033

The cardiovascular surgical devices market is expected to rise from around US$2.18 billion in 2025 to approximately US$2.86 billion by 2033, seeing a CAGR of 3.45% in this nine-year period. Factors such as increasing cardiovascular disease incidents, great developments in surgical technologies, and more pronounced interest in minimally invasive procedures are the key major influences on the market. These trends are going to influence cardiac healthcare positively on a global scale.

Cardiovascular surgery encompasses a category of surgical operations that target various diseases and conditions of the heart and vascular system. This specialized field includes coronary artery bypass grafting (CABG), heart valve repair or replacement, and surgeries for congenital heart defects. Surgical intervention in cardiovascular surgery has played a paramount role in the management of such conditions as coronary artery disease, heart failure, and aneurysms, which have greatly improved patient outcomes and increased quality of life.

The global increase in the prevalence of heart-related ailments because of lifestyle choices, aging of the population, and enhanced sensitization about heart health greatly influences the popularity of cardiovascular surgery. Improved surgical techniques and technologies, such as minimally invasive procedures and robotic-assisted surgeries, have added to the popularity by offering patients quicker recoveries and shorter lengths of stay in hospitals.

Most health facilities are now focusing on cardiovascular health, which means that more resources are being put into the surgical facilities and training programs. As demands for effective cardiac care continue to rise, cardiovascular surgery is still one of the leading edges of medical advancement, with research still going on to improve techniques and outcomes for patients worldwide.

Top Cardiovascular Surgical Devices Manufacturers

Abbott Laboratories

Headquarters: United States of America

Founded: 1888

Abbott Laboratories is one of the leading medical device and healthcare companies that discovers, develops, manufactures, and sells diversified products in the world market. The business portfolio of Abbott comprises gastroenterology and women's health, cardiovascular and metabolic health, pain management, central nervous system disorders, and many more. It also covers respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies along with point-of-care systems. Its portfolio also comprises rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Its product portfolio encompasses a wide range of vascular and structural heart needs as well as neuromodulation therapies. Abbott undertakes to market its products primarily through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retail buyers, among independent retailers. The company markets its products in North America, Latin America, the Middle East, Europe, the Asia-Pacific, and Africa.

Boston Scientific Corporation

Establishment: 1979

Headquarters: United States of America

Boston Scientific Corp (Boston Scientific) is a medical technology company that develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, urology, and vascular surgery. Boston Scientific supplies its products to hospitals, clinics, outpatient facilities, and medical offices across the world. The company has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It markets products directly and through a network of distributors and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas.

Edwards Lifesciences

Headquarters: United States of America

Founded: 1958

Edwards Lifesciences Corp (Edwards Lifesciences) is a medical technology company. It develops, manufactures and markets devices for structural heart disease, critical care and surgical monitoring. The company's products comprise surgical valve repair devices, surgical valve replacement, hemodynamic monitoring devices, transcatheter heart valves, pressure monitoring devices, and related instruments and accessories. Its products find application for various therapies such as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, enhanced surgical recovery, and for the management of clotting, hypotension and sepsis. The company markets products through a direct sales force and a network of independent distributors in North America, Europe and Asia-Pacific.

Cardinal Health Inc.

Headquarters: United States of America

Founded: 1971

Cardinal Health Inc (Cardinal Health) is a provider of integrated healthcare products and services. The company's major activities include the distribution of pharmaceuticals, manufacturing and distribution of medical and laboratory products, and providing performance and data solutions for healthcare facilities. It distributes branded and generic drugs, specialty medicines, over-the-counter healthcare and consumer products, medical equipment, surgical devices and laboratory products. The company operates nuclear pharmacies and cyclotron facilities and produces its own line of private branded medical and surgical products. Its customers also include retail customers such as chain and independent drug stores and pharmacies in supermarkets and mass merchandisers, hospitals, ambulatory care centers, physician offices, clinical laboratories and alternative care providers including mail order customers. The company operates in the US, Canada, Australia, China and Japan.

Medtronic PLC

Headquarters: Ireland

Founded: 1949

Medtronic plc (Medtronic) is a medical technology company that designs, develops, manufactures, and markets medical devices and solutions. The major activities of the company include research, design, manufacture, and sale of biomedical engineering products. It offers products used in the treatment of heart valve disorders, heart failure, coronary artery diseases, aortic, peripheral vascular, venous renal and neurological diseases, spine and musculoskeletal disorders, as well as diseases of the ear, nose, and throat. Medtronic also provides biologic solutions for the orthopedic and dental markets. The company provides its products to hospitals, third-party healthcare providers, clinics, institutions including governmental healthcare programs, distributors, and group purchasing organizations in Asia Pacific, Europe, the Americas, the Middle East, and Africa.

Product Launches in the Cardiovascular Surgical Devices Market

GE Healthcare

March 2025, GE HealthCare Technologies Inc. (GEHC) recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the American College of Cardiology (ACC) Annual Scientific Session & Expo. Furthermore, at the ACC, the company will showcase the latest version of its Cardiac Assessment System for Stress Testing (CASE) enabled by CardioSoft technology. GE HealthCare also will demonstrate the CardIQ Suite, a cohesive workflow that allows users to easily review calcium scoring and cardiac computed tomography angiography data, alongside the recently introduced AltiX AI edition of its Mac-Lab, CardioLab, and ComboLab products.

LivaNova PLC

Aug. 2025, LivaNova PLC today announced the commercial release of the Essenz(TM) Perfusion System in China, marking its second-largest market for heart-lung machines after the U.S. The system, recently approved by China's National Medical Products Administration, supports a data-driven, patient-tailored method to enhance clinical workflows and patient care during cardiopulmonary bypass procedures. In China, an estimated 330 million people have cardiovascular disease, while cardiac surgery is possible in more than 700 hospitals, and an estimated 185,000 adult and 23,500 pediatric extracorporeal circulation procedures will be performed in 2025.

SWOT Analysis of Company

Terumo Corporation

Strengths: Strong brand credibility, and commitment to the latest medical technologies.

Terumo Corporation's strength in the cardiovascular surgical devices market lies in its broad and innovative product portfolio, strong brand credibility, and commitment to advanced medical technology. The company is globally recognized for its excellence in cardiopulmonary systems, vascular grafts, and minimally invasive surgical instruments. Terumo's strong research and development (R&D) capabilities support continuous innovation that enables the company to introduce new solutions to improve patient safety and surgical precision. With a widely established global presence supported by a robust distribution network, it ensures broad access and a strong customer base across many healthcare segments. Additionally, emphasis on quality assurance and adherence to global regulatory standards further cements Terumo's status as a trusted brand among surgeons and healthcare institutions. Integration of digital and perfusion technologies further strengthens its competitive positioning, with Terumo thus being able to address an increasing global demand for efficient, patient-centric cardiovascular surgical solutions.

Getinge AB

Strengths include integrated health care solutions, innovative technologies, and strong global brand awareness.

Getinge AB's strengths in the cardiovascular surgical devices market arise from its integrated healthcare solutions, technological innovation, and strong global brand recognition. The company has established itself in the manufacture of advanced perfusion systems, heart-lung machines, and operating room technologies with a focus on enhancing clinical efficiency and patient outcomes. This makes the company uniquely placed in cardiovascular care, offering complete surgical solutions from operating tables and lights to cardiac assist devices. A significant investment in R&D and the commitment toward continuous product improvement at the company level drive the innovation pipeline for high performance and safety. Moreover, the well-established customer base, an advantage in global distribution networks, and excellent after-sales service reinforce Getinge's position as a partner of choice among hospitals and surgeons worldwide. Strict adherence to regulatory and quality standards further enhances its credibility to maintain leadership in the highly specialized cardiovascular surgical device market.

Recent Development in the Cardiovascular Surgical Devices Market

MicroPort Scientific Corporation

October 2025 - MicroPort(R) Coronary, a subsidiary of MicroPort Scientific Corporation, today announced that it has reached a record of more than 10 million global shipments and implantations of its coronary stent systems. This cements the company's leadership in interventional cardiology. The systems are used across more than 4,000 hospitals in China, including through programs such as the "FireSwallow Plan," which has increased the availability of advanced therapies in over 1,300 county-level hospitals. Since 2004, MicroPort has maintained the leading domestic market share, serving more than 6 million patients in China with a current market share of 43%.

Braun Melsungen AG

July 2025, B. Braun Medical Inc. officially announced the availability of the new Heparin Sodium Injections in the United States by adding 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL and 100 units/mL). This further cements B. Braun's position as the biggest provider of Heparin Premixed bags in the United States. The 250 mL and 500 mL bags will have a 2D enhanced barcode that will show the NDC number, lot number, expiration date, and improved spacing for better scanning accuracy and efficiency.

Sustainability Goal

Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc., is deeply committed to furthering sustainability through responsible business practices, environmental stewardship, and community impact. At the core of its sustainability objectives is to decrease the environmental footprint while helping the company boost operational efficiency and product innovation. Zimmer Biomet is committed to significantly decreasing greenhouse gas emissions, energy consumption, and water usage at all of its manufacturing sites worldwide. Transitioning to renewable energy and developing better waste management through recycling and material optimization form an important part of its sustainability strategy. The firm emphasizes sustainable product design: the design of orthopedic and medical solutions that minimize resource use and maximize patient benefit. Beyond the environmental, Zimmer Biomet fosters social responsibility through ethical governance and diversity, equity, and inclusion. Integrating sustainability into the long-term strategy, the company aspires to a resilient, responsible organization supportive of human health and the health of the planet.

W. L. Gore & Associates, Inc.

W. L. Gore & Associates, Inc. aims to achieve our aspiration through sustainable practices of innovation, caring for the environment, and responsible manufacturing. The company's sustainability objectives emphasize continuing to reduce environmental impact while maintaining product performance and quality, especially in medical, industrial, and consumer materials businesses. Gore is committed to reducing greenhouse gas emissions, energy consumption, and waste globally. At Gore, one major focus area in its sustainability journey is material innovation-developing more advanced polymers and fabrics with lower environmental impact that include PFAS alternatives and recyclable components. The company invests in sustainable sourcing and lifecycle management to ensure long-term ecological responsibility. Driven by an innovative culture, Gore is continuously improving to ensure safer chemistry, reducing a carbon footprint, and is operationally efficient. Moreover, it supports a strong commitment to community engagement, employee well-being, and good ethical governance. By taking these initiatives, W. L. Gore & Associates strives to balance technological excellence with environmental and social responsibility.

Market Segmentation

Cardiovascular Surgical Devices Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Cardiovascular Surgical Devices Market

Abbott Laboratories

Overview

• Company History and Mission
• Business Model and Operations

Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

• 1. Abbott Laboratories
• 2. Boston Scientific Corporation
• 3. Edwards Lifesciences
• 4. Cardinal Health Inc.
• 5. Medtronic PLC
• 6. GE Healthcare
• 7. LivaNova PLC
• 8. Terumo Corporation
• 9. Getinge AB
• 10. MicroPort Scientific Corporation
• 11. B. Braun Melsungen AG
• 12. Zimmer Biomet Holdings, Inc.
• 13. W. L. Gore & Associates, Inc.
• 14. Jarvik Heart, Inc.
• 15. Berlin Heart GmbH